Summitry LLC Purchases 492 Shares of Balchem Co. (NASDAQ:BCPC)

Summitry LLC lifted its position in shares of Balchem Co. (NASDAQ:BCPC) by 41.2% in the 4th quarter, Holdings Channel reports. The fund owned 1,687 shares of the basic materials company’s stock after buying an additional 492 shares during the quarter. Summitry LLC’s holdings in Balchem were worth $275,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in BCPC. FMR LLC lifted its holdings in Balchem by 944.3% during the third quarter. FMR LLC now owns 497,495 shares of the basic materials company’s stock valued at $87,559,000 after purchasing an additional 449,854 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Balchem during the 4th quarter valued at approximately $23,628,000. Raymond James Financial Inc. bought a new position in Balchem in the 4th quarter worth approximately $13,359,000. Barclays PLC boosted its holdings in Balchem by 405.8% in the 3rd quarter. Barclays PLC now owns 60,777 shares of the basic materials company’s stock worth $10,695,000 after buying an additional 48,762 shares during the period. Finally, Vanguard Group Inc. grew its stake in Balchem by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,961,487 shares of the basic materials company’s stock valued at $645,703,000 after buying an additional 42,693 shares in the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Price Performance

Shares of NASDAQ BCPC opened at $163.33 on Wednesday. The stock’s 50-day simple moving average is $164.97 and its two-hundred day simple moving average is $169.31. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03. The firm has a market capitalization of $5.31 billion, a P/E ratio of 41.56, a P/E/G ratio of 4.41 and a beta of 0.63. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19.

Balchem (NASDAQ:BCPC) last announced its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.08). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The company had revenue of $240.00 million during the quarter, compared to analysts’ expectations of $239.96 million. As a group, equities analysts anticipate that Balchem Co. will post 4.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BCPC. Sidoti upgraded Balchem to a “hold” rating in a research report on Tuesday, February 25th. StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 target price on shares of Balchem in a report on Monday, February 24th.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.